InflaRx N.V. (IFRX) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed InflaRx N.V. (IFRX) over the past year, gaining 45.9% versus a gain of 9.6%. Over five years, IFRX leads with a -35.2% price change compared with -96.5% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($259.0 million vs $235.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | ZNTL |
|---|---|---|
| Share price | $1.60 | $2.64 |
| Market cap | $235.79M | $259.04M |
| 1-day change | +4.58% | +5.18% |
| YTD return | +58.42% | +95.56% |
| 1-year return | +9.59% | +45.86% |
| 5-year return | -35.22% | -96.48% |
| EPS (TTM) | $-0.58 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $6.95 |
| 52-week low | $0.798 | $1.21 |
| Distance from 52-week high | -45.74% | -62.01% |
| Analyst consensus | none | buy |
| Avg. price target upside | +380.00% | +177.65% |
| Average volume | 795.73K | 1.21M |
| Shares outstanding | 147.37M | 98.12M |
| Employees | 65 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed IFRX by 36.3 percentage points over the past year.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
IFRX vs ZNTL FAQ
Which is bigger, InflaRx N.V. or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $259.04M compared with $235.79M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, IFRX or ZNTL?
ZNTL returned +45.86% over the past 12 months, compared with +9.59% for IFRX (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.